Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Cash from Financing Activities (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Cash from Financing Activities for 6 consecutive years, with -$1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 66.32% year-over-year to -$1.2 million, compared with a TTM value of -$13.4 million through Dec 2025, up 15.11%, and an annual FY2025 reading of -$13.4 million, up 15.11% over the prior year.
  • Cash from Financing Activities was -$1.2 million for Q4 2025 at Cytek Biosciences, down from $1.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $217.1 million in Q3 2021 and bottomed at -$33.8 million in Q4 2023.
  • Average Cash from Financing Activities over 5 years is $7.8 million, with a median of $17000.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities soared 22547.06% in 2022, then crashed 5438.06% in 2023.
  • Year by year, Cash from Financing Activities stood at $17000.0 in 2021, then skyrocketed by 22547.06% to $3.8 million in 2022, then plummeted by 976.73% to -$33.8 million in 2023, then soared by 89.22% to -$3.6 million in 2024, then soared by 66.32% to -$1.2 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CTKB at -$1.2 million in Q4 2025, $1.9 million in Q3 2025, and -$2.6 million in Q2 2025.